MedTrace Logo

Lovastatin in Treating Patients At High Risk of Melanoma

NCT00462280 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2014-10-31

Study results available
· View outcomes & findings →

Summary

The use of lovastatin may slow disease progression in patients at high risk of melanoma. It is not yet known whether lovastatin is more effective than a placebo in treating patients at high risk of melanoma. This randomized phase II trial studies how well giving lovastatin or placebo works in treating patients at high risk of melanoma.

Conditions

  • Precancerous Condition
  • Stage 0 Melanoma
  • Stage I Melanoma
  • Stage II Melanoma

Interventions

DRUG

lovastatin

Given PO

OTHER

placebo

Given PO

PROCEDURE

biopsy

Correlative studies

PROCEDURE

laboratory biomarker analysis

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Kenneth Linden · Chao Family Comprehensive Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2011-04-30
Completion
2012-02-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00462280 on ClinicalTrials.gov